CRISPR Therapeutics (NASDAQ: CRSP)
CRISPR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
2 Soaring Cathie Wood Stocks to Buy and Hold
These companies' market-beating fuel hasn't run out yet.
New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.
CRISPR Therapeutics is a promising mid-cap biotech stock with an approved product in its portfolio.
3 Monster Stocks to Hold for the Next 10 Years
Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the time. Every now and then, though, the right opportunity comes along.
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
These biotechs could finally come into their own by the end of the decade.
Top Biotech ETFs to Buy Now
Here are the five best biotech ETFs to invest in right now.
Investing in Gene-Editing Stocks
Could This Beaten-Down Stock Help You Become a Millionaire?
The company would need to maintain the strong momentum it's had this year for a long time.
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Breaking Down CRISPR Technology
What investors need to know.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.